TScan Therapeutics, Inc.
TScan Therapeutics, Inc.（TCRX）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
tcrx · 股价预测 · 8 位分析师（近3月）· FMP · 更新于 2026年6月9日
分析师评级与共识
基于过去 3 个月内 8 位华尔街分析师
Buy
8 位分析师
共识
评级分布
12 个月目标价
High
$12.00
Consensus
$7.50
+656.8% upside
Low
$3.00
Median: $7.5 · Last Close: $0.99
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$7.50
656.8% upside
High Target
$12
1110.9%
Low Target
$3
202.7%
Current Price
$0.99
as of today
Based on analyst price targets, the TCRX stock price prediction for the next 12 months ranges from $3 to $12. The consensus TCRX price forecast of $7.50 implies 656.8% upside from the current price of $0.99.
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.97 | ↓ 2.58% |
1-day model range: $0.95–$0.98. Peak: $0.98 (-2.58%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -47.6% |
| 2028 | — | -60.0% |
| 2029 | — | -64.8% |
| 2030 | — | -66.9% |
| 2031 | — | -67.9% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · TCRX · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-05 | Wedbush | Maintains | Outperform→Outperform |
| 2025-11-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-04 | Needham | Maintains | Buy→Buy |
| 2025-11-04 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2025-05-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-08 | Needham | Maintains | Buy→Buy |
| 2025-03-07 | Barclays | Maintains | Overweight→Overweight |
| 2025-03-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-05 | Needham | Maintains | Buy→Buy |
| 2024-12-11 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on TScan Therapeutics, Inc. (TCRX) stock. Of the recent 33 rating actions, 0 were upgrades and 1 were downgrades. 8 analysts currently cover TCRX.
分析师推荐趋势
TCRX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$8M
↓ 71.2% YoY
Revenue Next Year
$8M
↑ 3.3% YoY
EPS This Year
$-1.05
EPS Next Year
$-0.97
↓ 8.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast TCRX EPS of $-1.05 for the current fiscal year, based on estimates from 4 analysts. The TCRX revenue forecast is $8M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
TCRX 股价预测由两类独立数据源支撑：来自 8 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。TCRX 的共识目标价为 $7.50（+656.8% 上行空间），分析师共识为 Buy。
TCRX 的短期预测（明日）为 $0.97（-2.58%）。 TCRX 对 2030 年的预测区间为 $0–$0。
TScan Therapeutics, Inc. 在 NASDAQ 上市，代码 TCRX。TCRX 在 2027 年的整体展望偏积极，在覆盖分析师中约 88% 对应 Buy 共识。
常见问题
TCRX 预测 · 8 个问题根据 8 位华尔街分析师，TCRX 的 12 个月平均目标价为 $7.50，最高 $12.00、最低 $3.00。若有图表，中位目标价可在上方查看。相对当前价 $0.99，隐含约 +656.8% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.